Crypto
Ethereum Forecasts Better Price Development than Bitcoin for Now
Bitcoin and Ethereum are both lead global cryptocurrencies. The US SEC’s approval of Bitcoin ETFs and potential Ethereum ETFs has sparked interest. Analysts from K33 Research suggest Ethereum may outperform Bitcoin, evidenced by the ETH-BTC ratio. With Mt. Gox’s Bitcoin release looming, experts recommend considering overweighting ETH in portfolios for potential gains amid current market dynamics.
Bitcoin (BTC) and Ethereum (ETH) have been unchallenged at the top of the list of the most important global cryptocurrencies for years.
After the US Securities and Exchange Commission (SEC) approved trading in Bitcoin ETFs in January, last week it signaled that it would abandon its resistance to Ethereum ETFs. Investors are wondering whether this is also a good time to adjust their portfolios. Analysts such as those from K33 Research believe that a period has begun in which the price curve of Ethereum will develop better in relation to Bitcoin.
The benchmark here is the so-called ETH-BTC ratio, which shows how much Bitcoin an Ethereum is worth
The data on this, for example from CoinGecko, actually shows that the SEC decision on Ethereum ETFs on May 23rd triggered a boost. The indicator is currently a good 0.056 for Ethereum to Bitcoin. Expert Joshua Lim from Arbelos Markets sets 0.06 as the next target. K33 also sees ETH at an advantage over Bitcoin, at least for the trading debut of Ethereum ETFs, and believes it makes sense to overweight ETH when investing in crypto.
In addition to the developments in ETFs, experts also cite the topic of Mt. Gox as relevant to the price. A good 140,000 Bitcoins worth around 9 billion US dollars were set in motion this week, which were secured from the Mt. Gox hack of 2014. They are to be paid out to victims of the hack in the coming months, which could put price pressure on Bitcoin. Ethereum is not directly affected by this, which also suggests that ETH is about to enter a phase in which the number two cryptocurrency outperformed Bitcoin.
Conclusion: Ethereum and Bitcoin – switching could be worthwhile
One thing is clear: Bitcoin and, in the future, Ethereum have a unique selling point with their ETFs in a regulated environment, which also attracts institutional investors. The ETH-BTC ratio as a guide for investment strategies works even when the price curves are falling.
So anyone who also believes that Ethereum is currently taking over the momentum can do the math to see whether a readjustment of their individual portfolio could pay off. Of course, factors such as tax issues and fees are also important. In the long term, however, there are no signs that Ethereum could shake Bitcoin’s throne as the leading crypto currency; the main focus is on taking advantage of a potentially profitable market situation.
__
(Featured image by Traxer via Unsplash)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in BLOCK-BUILDERS.DE. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us
-
Biotech1 week ago
Laminar Pharma Raises 5.9 Million in a New Round of Financing
-
Crypto12 hours ago
Bitcoin ETF Options Debut in the U.S.: Is a New All-Time High on the Horizon?
-
Biotech2 weeks ago
Leitat Purchases ReadyCell through MedTech Innovation on Advanced Medicine
-
Fintech6 days ago
Metadev3 Now Becomes a Validator on Tezos